Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

OrbusNeich Starts China Trial of COMBO™ Dual Therapy Stent

publication date: Jul 21, 2015
OrbusNeich, headquartered in Hong Kong, has enrolled the first patient in a China clinical trial of its COMBO™ Dual Therapy Stent. The COMBO stent has a coating of anti-CD34 antibodies to promote endothelialization of the stent, combined with sirolimus drug elution to deter the blood vessel from re-closing over the longer term. OrbusNeich, which makes medical devices for the vascular market, has manufacturing facilities in Shenzhen and the Netherlands, plus an R&D operation in Fort Lauderdale, Florida. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here